Premium
Clinical evaluation of specific γ‐GTP isoenzyme in patients with hepatocellular carcinoma
Author(s) -
Sawabu Norio,
Nakagen Masatoshi,
Ozaki Kenji,
Wakabayashi Tokio,
Toya Daishu,
Hattori Nobu,
Ishii Masaru
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830115)51:2<327::aid-cncr2820510227>3.0.co;2-c
Subject(s) - hepatocellular carcinoma , medicine , gtp' , stage (stratigraphy) , incidence (geometry) , gastroenterology , isozyme , carcinoma , pathology , oncology , enzyme , biology , biochemistry , paleontology , physics , optics
The authors evaluated specific γ‐GTP isoenzyme (specific γ‐GTP) found in sera of patients with hepatocellular carcinoma (HCC). In addition to band II and II' which had been reported in our previous publication, band I' also had a high specificity for HCC. One or more of these bands were detectable in 109 (55%) of 200 patients with HCC, but only in seven (3%) of 279 patients with other hepatobiliary diseases. Specific γ‐GTP was found in 38% of HCC patients with alpha‐fetoprotein (AFP) levels below 400 ng/ml. The incidence of this isoenzyme was independent of the clinical stage as classified by liver scanning. Even in Stage I, where filling defects were not seen, the incidence was 52%. We conclude that the specific γ‐GTP is useful in diagnosis of HCC patients with low levels of AFP or at a relatively early stage.